Search details
1.
Cost-effectiveness of human papillomavirus (HPV) vaccination in Burkina Faso: a modelling study.
BMC Health Serv Res
; 23(1): 1338, 2023 Dec 01.
Article
in English
| MEDLINE | ID: mdl-38041075
2.
The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70.
Clin Infect Dis
; 74(8): 1459-1467, 2022 04 28.
Article
in English
| MEDLINE | ID: mdl-34283213
3.
The Adjuvanted Recombinant Zoster Vaccine in Adults Aged ≥65 Years Previously Vaccinated With a Live-Attenuated Herpes Zoster Vaccine.
J Infect Dis
; 224(7): 1139-1146, 2021 10 13.
Article
in English
| MEDLINE | ID: mdl-32103273
4.
Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine: Persistence and Anamnestic Response to Additional Doses Administered 10 Years After Primary Vaccination.
J Infect Dis
; 224(12): 2025-2034, 2021 12 15.
Article
in English
| MEDLINE | ID: mdl-32502272
5.
Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials.
Rheumatology (Oxford)
; 60(3): 1226-1233, 2021 03 02.
Article
in English
| MEDLINE | ID: mdl-32910152
6.
Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy Adults.
J Infect Dis
; 214(11): 1717-1727, 2016 Dec 01.
Article
in English
| MEDLINE | ID: mdl-27609809
7.
Immunogenicity and Safety of an EB66 Cell-Culture-Derived Influenza A/Indonesia/5/2005(H5N1) AS03-Adjuvanted Vaccine: A Phase 1 Randomized Trial.
J Infect Dis
; 212(4): 531-41, 2015 Aug 15.
Article
in English
| MEDLINE | ID: mdl-25722291
8.
Safety and immunogenicity of Innovax bivalent human papillomavirus vaccine in girls 9-14 years of age: Interim analysis from a phase 3 clinical trial.
Vaccine
; 42(9): 2290-2298, 2024 Apr 02.
Article
in English
| MEDLINE | ID: mdl-38431444
9.
Adjuvanted recombinant zoster vaccine decreases herpes zoster-associated pain and the use of pain medication across 3 randomized, placebo-controlled trials.
Pain
; 164(4): 741-748, 2023 04 01.
Article
in English
| MEDLINE | ID: mdl-36066965
10.
Impact, cost-effectiveness, and budget implications of HPV vaccination in Kenya: A modelling study.
Vaccine
; 41(29): 4228-4238, 2023 06 29.
Article
in English
| MEDLINE | ID: mdl-37296015
11.
Impact and Cost-Effectiveness of Alternative Human Papillomavirus Vaccines for Preadolescent Girls in Mozambique: A Modelling Study.
Vaccines (Basel)
; 11(6)2023 Jun 02.
Article
in English
| MEDLINE | ID: mdl-37376447
12.
State-of-the-Science of human papillomavirus vaccination in women with human immunodeficiency Virus: Summary of a scientific workshop.
Prev Med Rep
; 35: 102331, 2023 Oct.
Article
in English
| MEDLINE | ID: mdl-37576844
13.
Association Between Hemagglutination Inhibition Antibody Titers and Protection Against Reverse-Transcription Polymerase Chain Reaction-Confirmed Influenza Illness in Children 6-35 Months of Age: Statistical Evaluation of a Correlate of Protection.
Open Forum Infect Dis
; 9(2): ofab477, 2022 Feb.
Article
in English
| MEDLINE | ID: mdl-35083365
14.
Prevalence of human papillomavirus infection and associated risk factors in young women in Brazil, Canada, and the United States: a multicenter cross-sectional study.
Int J Gynecol Pathol
; 30(2): 173-84, 2011 Mar.
Article
in English
| MEDLINE | ID: mdl-21293281
15.
Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study.
Hum Vaccin
; 7(12): 1374-86, 2011 Dec.
Article
in English
| MEDLINE | ID: mdl-22048171
16.
Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years.
Hum Vaccin
; 7(12): 1359-73, 2011 Dec.
Article
in English
| MEDLINE | ID: mdl-22048172
17.
Safety of the adjuvanted recombinant zoster vaccine in adults aged 50 years or older. A phase IIIB, non-randomized, multinational, open-label study in previous ZOE-50 and ZOE-70 placebo recipients.
Vaccine
; 39(1): 6-10, 2021 01 03.
Article
in English
| MEDLINE | ID: mdl-33277059
18.
Immune responses to the adjuvanted recombinant zoster vaccine in immunocompromised adults: a comprehensive overview.
Hum Vaccin Immunother
; 17(11): 4132-4143, 2021 11 02.
Article
in English
| MEDLINE | ID: mdl-34190658
19.
Non-neutralizing antibody responses following A(H1N1)pdm09 influenza vaccination with or without AS03 adjuvant system.
Influenza Other Respir Viruses
; 15(1): 110-120, 2021 01.
Article
in English
| MEDLINE | ID: mdl-32889792
20.
Impact of Reactogenicity After Two Doses of Recombinant Zoster Vaccine Upon Physical Functioning and Quality of Life: An Open Phase III Trial in Older Adults.
J Gerontol A Biol Sci Med Sci
; 76(3): 485-490, 2021 02 25.
Article
in English
| MEDLINE | ID: mdl-32530462